IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes following Early-Line Cilta-cel Treatment Authors: Sridevi Rajeeve, Saurabh P Nagar, Sabyasachi Ghosh, Victoria Alegria, Justin Hayne, Bruno Emond, Jessica Maitland, Zaina P Qureshi, Larry D Anderson Published: 2026 ABSTRACT AbstractIntroductionCiltacabtagene autoleucel (cilta-cel) has demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma (RRMM), supporting the goal of sustained minimal residual disease (MRD) negativity as a marker for potential functional cure, characterized by prolonged treatment-free disease control. Initially, cilta-cel was approved in the US for RRMM after ≥ 4 prior lines of therapy (LOT), and after 1–3 prior LOT in April 2024. This study describes real-world clinical outcomes, including MRD negativity, of cilta-cel after 1–3 prior LOT.MethodsElectronic medical records from Loopback Analytics (April 2024–May 2025) were used, supplemented with physician notes. Adults with RRMM treated with cilta-cel after 1–3 prior LOT were included. Post-infusion outcomes (cilta-cel response, MRD negativity, disease progression, and overall survival) were assessed overall and by bridging therapy (BT) regimen.ResultsOverall, 120 patients were included (median age 67 years, 43.3% female). Prior to infusion, 87.5% received BT, including alkylator-based (28.6%), IMiD ± mAb-based (25.7%), PI-based (20.0%), talquetamab (14.3%), and other regimens (11.4%). Over a median follow-up of 5.8 months, among patients with a response assessment (81.7%), the overall response rate (ORR) to cilta-cel was 98.0%, including 72.4% with complete response. Among 36 MRD-evaluable patients, MRD negativity (10–5) was achieved in 35 (97.2%), with a median time to MRD negativity of 80.0 days. At last follow-up, 94.2% of patients remained progression-free, 95.8% had not initiated subsequent treatment, and 99.2% remained alive. Across BT regimens, ORR to cilta-cel was 95–100% and MRD negativity was achieved in 80–100%.ConclusionsThis real-world study demonstrates the effectiveness of cilta-cel in RRMM after 1–3 prior LOT. High rates of response and MRD negativity were reported overall and across BT regimens, including talquetamab. Longer follow-up with repeated MRD measurements may provide further insights into response durability and survival outcomes, helping to contextualize the potential for a functional cure.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s40487-026-00455-6.Keywords: Bridging therapy, CAR-T, Functional cure, Minimal residual disease negativity, Real world Key Summary Points Why carry out this study? This study aimed to evaluate real-world clinical outcomes, including minimal residual disease (MRD) negativity, among patients with relapsed/refractory multiple myeloma (RRMM) treated with ciltacabtagene autoleucel (cilta-cel) after 1–3 prior lines of therapy (LOT), overall and across bridging therapy regimens.Up until April 2024, cilta-cel was only available in the USA for later-line therapy after ≥ 4 prior LOT, but since then it has become available after 1–3 prior LOT. What was learned from the study? Cilta-cel demonstrated high effectiveness among patients with evaluable outcomes, with a high rate of MRD negativity (10–5; 35/36 [97.2%]), a 98.0% overall response rate, and a 72.4% complete response rate, which was consistent across bridging therapy regimens.These findings align with those reported in pivotal trials, supporting cilta-cel’s use in earlier LOT and its potential for sustained disease control.MRD negativity may be an important prognostic marker for cilta-cel outcomes, and broader adoption in clinical practice is needed to support long-term assessment, inform precision-based treatment decisions, and reduce treatment burden by enabling treatment-free disease control after a single infusion. Digital Features This article is published with digital features, including a graphical abstract, to facilitate understanding of the article. To view digital features for this article, go to https://doi.org/10.6084/m9.figshare.32740554. Introduction Multiple myeloma (MM) is a hematologic malignancy that has historically been considered incurable, with patients experiencing recurrent relapses and disease progression, requiring treatment with multiple lines of therapy (LOT) [1]. As disease becomes refractory to multiple drug classes, achieving durable disease control has traditionally posed a significant clinical challenge [2]. Ongoing therapeutic advances over recent decades have expanded treatment options and improved survival outcomes for patients with MM [2–4]. More recently, the advent of chimeric antigen receptor T-cell (CAR-T) therapies has transformed the treatment landscape for patients with relapsed/refractory MM (RRMM). Currently approved CAR-T therapies such as ciltacabtagene autoleucel (cilta-cel) have demonstrated deep and durable responses following a single infusion, with sustained disease control based on minimal residual disease (MRD) negativity in the absence of ongoing therapy [5–7]. These findings support the emerging goal of a functional cure in RRMM, characterized by prolonged treatment-free disease control with no detectable disease using current methods of assessment [6, 8]. MRD negativity has emerged as a key prognostic marker, reflecting the absence of residual malignant cells in bone marrow, as measured using sensitive techniques such as next-generation sequencing (NGS) or flow cytometry [9]. MRD negativity at 10–5 and 10–6 thresholds has been strongly associated with improved long-term survival outcomes, such as progression-free survival (PFS) and overall survival (OS), early within the disease course (e.g., within 100 days of therapy) and particularly when sustained over time [10, 11]. Reflecting these advances, the International Myeloma Working Group (IMWG) incorporated standardized MRD negativity definitions into RRMM response criteria, supporting broader adoption in clinical trials [12, 13]. Recently, MRD negativity has also been accepted by the US Food and Drug Administration (FDA) as an early clinical trial endpoint to support accelerated approval for novel MM treatments [14]. Cilta-cel has demonstrated significantly improved patient outcomes compared with standard of care treatments [15–17]. While initially approved in the US as later-line treatment for RRMM, its indication was expanded in April 2024, to lenalidomide-refractory patients after treatment with ≥ 1 prior LOT, on the basis of results from the CARTITUDE-4 pivotal trial [15, 17]. In the second interim trial analysis, over a median follow-up of 33.6 months, a significantly higher proportion of MRD-evaluable patients receiving cilta-cel achieved MRD negativity at the 10–5 threshold (89% versus 38%) and at the 10–6 threshold (86% versus 19%) relative to standard of care [15]. In both clinical trial and real-world settings, most patients treated with cilta-cel receive bridging therapy prior to infusion to maintain disease control and decrease tumor burden during the manufacturing interval, which may increase CAR-T efficacy and reduce toxicity [17–22]. Notably, the more favorable safety profile observed with earlier-line cilta-cel infusion in CARTITUDE-4 relative to CARTITUDE-1 (among patients with ≥ 3 prior LOT) may partially reflect the effectiveness of bridging therapy [15]. This may be more easily achieved in earlier-line patients with relatively lower treatment refractoriness than in later-line patients, which supports efforts to maximize treatment benefit by using effective therapies early in the disease course [17]. These observations suggest that earlier treatment and bridging strategy may be important determinants of both safety and depth of response, supporting the clinical goal of achieving MRD negativity within patients treated with cilta-cel in earlier-line settings. The ability to achieve MRD negativity following a single infusion without requiring ongoing therapy distinguishes CAR-T from conventional treatment as a potential functional cure in RRMM [6, 8]. However, real-world data in earlier LOT evaluating post-infusion outcomes, including MRD negativity, stratified by the type of bridging regimen received are lacking, particularly given the individualized nature of bridging therapy in clinical practice [18, 23]. To address these knowledge gaps, this study aimed to describe real-world clinical outcomes, including MRD negativity, among patients with RRMM who received cilta-cel after 1–3 prior LOT overall, and stratified by bridging therapy regimen. Methods Data Source De-identified electronic medical records (EMR) from Loopback Analytics, supplemented with unstructured physician notes, were used to identify patients who received cilta-cel following 1–3 prior LOT between 5 April 2024 (FDA approval date for early-line use) and 31 May 2025. To evaluate treatment history prior to cilta-cel infusion, all available records starting from 28 February 2017 were used. Loopback Analytics captures information from both academic and community-based healthcare settings across the US, and contains information on patient demographics, clinical characteristics, treatment patterns, biomarker data, and clinical outcomes such as treatment response, MRD, progression, and survival. To our knowledge, the data included in this study captured patients with commercial use of cilta-cel (CARVYKTI®) in routine care, with dose, timing, and route of administration consistent with US label [24]. This study was considered exempt from review by an institutional review board as it involved only the secondary use of fully de-identified data in compliance with the Health Insurance Portability and Accountability Act (HIPAA), specifically, 45 CFR § 164.514. Additionally, this study did not involve interaction with human subjects or access to identifiable private information. All structured and unstructured data, including physician notes, were de-identified by Loopback Analytics prior to access by the study team or third-party data abstractor, and no identifiable patient information was available to investigators at any time. Loopback Analytics’ de-identification process included removal and obfuscation of protected health information in accordance with HIPAA standards, including removal or transformation of HIPAA identifiers and replacement of direct identifiers with synthetic surrogates using a “hiding in plain sight” methodology. Accordingly, the study was considered exempt under 45 CFR § 46.104(d)(4). Study Design This retrospective cohort study evaluated adult patients with RRMM treated with cilta-cel after 1–3 prior LOT. The index date was defined as the date of cilta-cel infusion on or after 5 April 2024, with the baseline period spanning the 12 months prior to infusion. Outcomes were assessed from infusion until the earliest of death, last medical encounter, or end of data availability (Fig. 1). Study design. cilta-cel ciltacabtagene autoleucel, FDA Food and Drug Administration, LOT lines of therapy. (1) All available data from 28 February 2017 (i.e., the start of the data cut) were used to ascertain patients’ prior LOT before the initiation of cilta-cel. (2) Patients treated with cilta-cel were identified from 5 April 2024 (i.e., FDA approval for cilta-cel in early LOT) to 31 May 2025 (i.e., the end of the data cut) Study Population Adult patients with MM (defined as having an International Classification of Diseases, Tenth Revision, Clinical Modification [ICD-10-CM] diagnosis code for MM [C90.0] on ≥ 2 separate dates including ≥ 1 preceding infusion, to reduce the likelihood of rule-out diagnoses and false MM identification) with ≥ 12 months between the first medical encounter (for any reason) and infusion were included if they received cilta-cel after 1–3 prior LOT on or after 5 April 2024. Patients were also required to have information abstracted from unstructured physician notes. Patients were excluded if they had no evidence of lymphodepleting chemotherapy, had evidence of clinical trial participation during the cilta-cel LOT, had a diagnosis of amyloidosis prior to infusion, or had evidence of prior CAR-T therapy. Study Outcomes and Statistical Analysis Patient demographic and clinical characteristics were descriptively reported over the 12-month baseline period, using the medical record closest to infusion. Structured EMR were used to assess clinical characteristics such as Quan-Charlson Comorbidity Index (Quan-CCI) [25], frailty index score in the three months prior to infusion, and CRAB symptoms (i.e., calcium elevation, renal insufficiency, anemia, and bone lesions) in the month prior to infusion. Frailty index score was evaluated on the basis of an algorithm for patients with MM developed by Patel et al., using a real-world claims database, which includes 31 conditions and is scored from 0–1 [26]. Unstructured physician notes were leveraged to describe infusion setting, Eastern Cooperative Oncology Group (ECOG) status, extramedullary disease (EMD), cytogenetic information, clonal plasma cells, and involved to uninvolved serum free light chain ratio. Receipt of stem cell transplant and bridging therapy prior to infusion were also assessed on the basis of physician notes. Response to bridging therapy (based on best response in unstructured notes) was described and stratified by bridging therapy regimen according to the following categories: alkylator-based, immunomodulatory agent (IMiD) ± monoclonal antibody (mAb)-based, proteasome inhibitor (PI)-based, talquetamab, and other regimens. Post-infusion outcomes including cilta-cel response (based on best response), MRD negativity, time from cilta-cel infusion to first report of MRD negativity, progressive disease, initiation of subsequent treatment, and OS, were assessed from physician notes, and descriptively reported among all patients and stratified by bridging therapy regimen. Response to bridging therapy and to cilta-cel was assessed on the basis of physician report, with IMWG criteria applied when available. MRD negativity was assessed on the basis of physician report using flow cytometry or NGS for negativity at the 10–5 threshold [12] and using next-generation flow cytometry or NGS for negativity at the 10–6 threshold [27, 28], when available. Results Baseline Characteristics Overall, 120 patients treated with cilta-cel after 1–3 prior LOT were included in the study (Fig. 2). The median age was 67 years, 43.3% were female patients, 68.3% were white, and 55.0% were Medicare-insured (Table 1). During the baseline period, the median Quan-CCI was 2.0; 13.3% of patients had mild-to-severe frailty, while 20.8% were prefrail, and 65.8% were nonfrail. Additionally, 31.7% of patients had ≥ 1 CRAB symptom in the month prior to infusion. Study population selection. CAR-T chimeric antigen receptor T-cell, cilta-cel ciltacabtagene autoleucel, HCPCS Healthcare Common Procedure Coding System, ICD-10CM International Classification of Disease, 10th Revision, Clinical Modification, LOT lines of therapy, MM multiple myeloma. (1) Evidence of participation in clinical trial was identified based on ICD-10-CM: Z00.6; HCPCS: S9988, S9990, S9991, S9992, S9994, S9996 Table 1Baseline characteristics1–3 prior LOTN = 120Demographic characteristicsAge (years), mean ± SD [median]65.5 ± 8.4 [67.0]Sex, n (%) Male68 (56.7) Female52 (43.3)Race, n (%) White82 (68.3) Black9 (7.5) Asian6 (5.0) Other/unknown23 (19.2)US region, n (%) West72 (60.0) Midwest27 (22.5) Northeast19 (15.8) South1 (0.8) Unknown1 (0.8)Insurance plan, n (%) Medicare66 (55.0) Commercial41 (34.2) Medicaid5 (4.2) Managed care5 (4.2) Other/unknown3 (2.5)Year of index date, n (%) 202479 (65.8) 202541 (34.2)Clinical characteristicsNumber of prior LOT, n (%) 1 prior LOT43 (35.8) 2 prior LOT43 (35.8) 3 prior LOT34 (28.3)Quan-CCI, mean ± SD [median]3.1 ± 1.7 [2.0]Frailty index score (3 months pre-index)a, mean ± SD [median]0.09 ± 0.09 [0.06] Nonfrail (0 to 0.1)79 (65.8) Prefrail (0.11 to 0.20)25 (20.8) Mild-to-severe frailty (> 0.2)16 (13.3)CRAB symptoms (1 month pre-index), n (%)38 (31.7) Anemia37 (30.8) Renal impairment3 (2.5) Bone lesions2 (1.7) Hypercalcemia2 (1.7)ECOG status assessment, n (%)110 (91.7) 042 (38.2) 159 (53.6) ≥ 29 (8.2) Time from evaluation to infusion (months), mean ± SD [median]0.7 ± 1.4 [0.2]EMD status assessment, n (%)85 (70.8) EMD28 (32.9)Cytogenetic information assessment, n (%)65 (54.2) High-risk cytogenetic abnormalitiesb38 (58.5) TP53 mutation7 (10.8) del(17p)17 (26.2) del(1p32)6 (9.2) t[4;14]14 (21.5) t[14;16]3 (4.6) t[14;20]2 (3.1) 1q (amplification or gain)49 (75.4) Clonal plasma cells test, n (%)61 (50.8) Clonal plasma cells percentage, mean ± SD [median] (min, max)19.0 ± 23.2 [9.0](1.0, 90.0) Time from test to infusion (months), mean ± SD [median]3.2 ± 4.8 [1.8] Involved:uninvolved serum free light chain ratio reported, n (%)111 (92.5) Ratio ≥ 10015 (13.5) Prior SCT information assessed, n (%)118 (98.3) Prior SCT90 (76.3) Cilta-cel infusion setting assessed, n (%)116 (96.7) Inpatient67 (57.8) Outpatient49 (42.2)CCI Charlson Comorbidity Index, cilta-cel ciltacabtagene autoleucel, CRAB calcium elevation, renal insufficiency, anemia, and bone lesions, ECOG Eastern Cooperative Oncology Group, EMD extramedullary disease, EMR electronic medical records, LOT lines of therapy, SCT stem cell transplant, SD standard deviation, US United StatesaFrailty index score was evaluated with structured EMR data based on an algorithm for patients with multiple myeloma by Patel et al., which includes 31 conditions and is scored from 0 to 1bDefined as evidence of del(17p) in sorted plasma cells ≥ 20%, TP53 mutation, biallelic del(1p32) or any two of the following abnormalities: t[4;14] or t[14;16] or t[14;20], 1q (gain or amplification), monoallelic del(1p32) Baseline characteristics 19.0 ± 23.2 [9.0] (1.0, 90.0) CCI Charlson Comorbidity Index, cilta-cel ciltacabtagene autoleucel, CRAB calcium elevation, renal insufficiency, anemia, and bone lesions, ECOG Eastern Cooperative Oncology Group, EMD extramedullary disease, EMR electronic medical records, LOT lines of therapy, SCT stem cell transplant, SD standard deviation, US United States aFrailty index score was evaluated with structured EMR data based on an algorithm for patients with multiple myeloma by Patel et al., which includes 31 conditions and is scored from 0 to 1 bDefined as evidence of del(17p) in sorted plasma cells ≥ 20%, TP53 mutation, biallelic del(1p32) or any two of the following abnormalities: t[4;14] or t[14;16] or t[14;20], 1q (gain or amplification), monoallelic del(1p32) Among patients with reported information on the corresponding clinical characteristic, 8.2% had an ECOG score ≥ 2 (evaluated at a median of 0.2 months pre-infusion), 32.9% had EMD, 58.5% had high-risk cytogenetic abnormalities, and 13.5% had an involved to uninvolved serum free light chain ratio ≥ 100 (Table 1). The median clonal plasma cell percentage was 9.0%, evaluated at a median of 1.8 months prior to infusion. Additionally, most patients (76.3%) received a prior stem cell transplant, and cilta-cel infusion was commonly administered in both inpatient (57.8%) and outpatient (42.2%) settings. Bridging Therapy Among 120 patients included in the study, 87.5% received bridging therapy prior to cilta-cel infusion (Table 2). The most common bridging regimens were alkylator-based (28.6%), IMiD ± mAb-based (25.7%), PI-based (20.0%), and talquetamab (14.3%); 11.4% received other regimens. Most patients with alkylator-based bridging therapy received low-dose alkylator-based regimens with cyclophosphamide. Other regimens included daratumumab monotherapy, venetoclax monotherapy, daratumumab and venetoclax, and selinexor monotherapy (Table 2). Additional information on bridging therapy by type of regimen is described in Supplementary Table 1. Table 2Bridging therapy1–3 prior LOTN = 120Received bridging therapy, n (%)105 (87.5) Bridging therapy regimen typea, n (%) Alkylator-based30 (28.6) IMiD ± mAb-based27 (25.7) PI-based21 (20.0) Talquetamab15 (14.3) Otherb12 (11.4) Evaluable response to bridging therapy, n (%)51 (48.6) Overall response ratec34 (66.7) Complete response5 (9.8) Partial response29 (56.9)IMiD immunomodulatory drug, LOT lines of therapy, mAb monoclonal antibody, PI proteasome inhibitoraReported as mutually exclusive categories based on the agents received, using the following regimen categories: alkylator-based, IMiD ± mAb-based, PI-based, talquetamab, and other regimensbOther bridging therapy regimens included daratumumab monotherapy (N = 8), venetoclax monotherapy (N = 2), daratumumab and venetoclax (N = 1), and selinexor monotherapy (N = 1)cAmong patients with a response assessment. Overall response was evaluated on the basis of physician-reported best response Bridging therapy IMiD immunomodulatory drug, LOT lines of therapy, mAb monoclonal antibody, PI proteasome inhibitor aReported as mutually exclusive categories based on the agents received, using the following regimen categories: alkylator-based, IMiD ± mAb-based, PI-based, talquetamab, and other regimens bOther bridging therapy regimens included daratumumab monotherapy (N = 8), venetoclax monotherapy (N = 2), daratumumab and venetoclax (N = 1), and selinexor monotherapy (N = 1) cAmong patients with a response assessment. Overall response was evaluated on the basis of physician-reported best response Among 51 patients with a reported response to bridging therapy, the overall response rate (ORR) to bridging therapy based on physician-reported best response was 66.7%, including 9.8% of patients achieving complete response and 56.9% achieving partial response (Table 2). Post-infusion Outcomes Over a median (interquartile range) follow-up of 5.8 (3.2–8.6) months, 98 patients (81.7%) had a reported response assessment to cilta-cel (Table 3). Among patients with a response assessment (based on physician-reported best response), the ORR was 98.0%, including 72.4% of patients achieving complete response and 25.5% achieving partial response. ORR was consistent across patients receiving different bridging therapy regimens, with nearly all patients achieving a response to cilta-cel (95–100%; Supplementary Table 1). Table 3Post-infusion outcomes1–3 prior LOTN = 120Duration of follow-up (months), mean ± SD [median]5.8 ± 3.5 [5.8]Evaluable response to cilta-cel, n (%)98 (81.7) Overall response ratea96 (98.0) Complete response71 (72.4) Partial response25 (25.5)MRD-evaluable patients, n (%)36 (30.0) MRD statusb,c MRD negative (10–5)35 (97.2) Time to MRD negativity (days), mean ± SD [median]89.2 ± 51.5 [80.0] MRD positive1 (2.8)Initiated subsequent LOT, n (%)5 (4.2)Death, n (%)1 (0.8)cilta-cel ciltacabtagene autoleucel, LOT lines of therapy, MRD minimal residual disease, SD standard deviationaAmong patients with a response assessment. Overall response was evaluated based on physician-reported best responsebAmong MRD-evaluable patientscA subset of patients (N = 4) with evaluable MRD response was reported as MRD negative (10–6) Post-infusion outcomes cilta-cel ciltacabtagene autoleucel, LOT lines of therapy, MRD minimal residual disease, SD standard deviation aAmong patients with a response assessment. Overall response was evaluated based on physician-reported best response bAmong MRD-evaluable patients cA subset of patients (N = 4) with evaluable MRD response was reported as MRD negative (10–6) Among 36 MRD-evaluable patients, MRD negativity at a 10–5 threshold was achieved in 97.2% of patients, with a median time to MRD negativity of 80.0 days post-infusion (Fig. 3; Table 3). Consistent with these findings, MRD negativity rates were similar across patients receiving different bridging therapy regimens, with 80–100% of patients achieving MRD negativity. The median time to MRD negativity was numerically shortest for other bridging regimens, PI-based regimens, and talquetamab, at 43.0, 62.5, and 68.0 days following infusion, respectively (Supplementary Table 1). Response to cilta-cel and post-infusion MRD. MRD minimal residual disease. (1) Among patients with a response assessment. Overall response was evaluated on the basis of physician-reported best response. (2) Among MRD-evaluable patients Lastly, among all 120 patients included in the study, 94.2% of patients remained progression-free, 95.8% had not initiated subsequent treatment, and 99.2% remained alive by the end of follow-up, on the basis of available records (Table 3). Discussion In this real-world EMR-based retrospective study of patients with RRMM treated with cilta-cel after 1–3 prior LOT, high response rates were observed; nearly all patients with available response assessments achieved at least partial response to cilta-cel, and over 70% attained complete response. Similarly, among the 36 MRD-evaluable patients, nearly 100% of patients achieved MRD negativity at the 10–5 threshold, with a median time to MRD negativity of 80 days, highlighting the deep and rapid responses achieved with cilta-cel. The majority of patients received bridging therapy prior to infusion, including approximately 15% of patients receiving talquetamab as bridging therapy. Clinical outcomes following cilta-cel infusion were favorable across bridging therapy subgroups. To our knowledge, this is one of the largest real-world studies to evaluate MRD negativity among patients with RRMM receiving CAR-T therapy in earlier LOT, providing important early data in this setting. The high rates of MRD negativity observed in real-world clinical practice are consistent with those reported in clinical trials [15], supporting the potential of cilta-cel to induce deep and durable responses. These real-world findings also corroborate the favorable response observed in CARTITUDE-4, where 84.6% of patients randomized to cilta-cel achieved overall response [17]. Importantly, a difference for this real-world analysis is that we did not have access to outcomes for patients who were intended for CAR-T but never received it while the CARTITUDE-4 study used an intention-to-treat analysis. Long-term remission was observed in the second interim analysis of the trial, with 30-month PFS and OS rates of 59.4% and 76.4%, respectively, reflecting durable response over time [15]. Kaplan–Meier analyses of PFS and OS were not feasible in the present study owing to limited follow-up given cilta-cel’s more recent approval in the early-line setting. However, low rates of disease progression, subsequent LOT initiation, and death suggest encouraging early real-world effectiveness. Although long-term follow-up is limited, the high MRD negativity rates observed in our study can provide an early indication of long-term clinical outcomes. In this study, 97.2% of the 36 evaluable patients achieved MRD negativity, aligning with almost 90% of patients in CARTITUDE-4 [15]. The median time to MRD negativity of 80 days observed in this study falls within the range of early response assessments performed 56 days post-infusion in CARTITUDE-4 [15] and the 90-day post-infusion landmark referenced in other reports [29]. As described, MRD negativity is a predictor of significant improvement in PFS and OS compared with MRD-positive patients, particularly when sustained over time [10]. In this context, the high rates of MRD negativity attained rapidly after infusion among patients treated with cilta-cel in this real-world study, consistent with clinical trials, may be indicative of the potential for long-term treatment-free disease control. A key component to the definition of a functional cure that could not be evaluated in this study is sustained MRD negativity over time, as patient follow-up remains ongoing and longitudinal assessments of MRD were not collected at this time [6, 10, 30]. However, the current real-world study adds to the body of evidence and complements the findings from the second interim analysis of CARTITUDE-4, which reported that over half of patients with initial MRD assessments in the cilta-cel group achieved sustained MRD negativity for at least 1 year, suggesting that a single infusion can induce deep, sustained responses without the need for ongoing treatment [15]. Unlike conventional therapies, which typically require continuous or maintenance treatment to maintain remission and often fail to sustain MRD negativity over time, CAR-T therapies such as cilta-cel offer a distinct therapeutic paradigm, consistent with the definition of a functional cure. Despite increasing recognition of MRD negativity as a key prognostic endpoint by regulatory agencies and the IMWG in clinical trial settings [12, 14], its integration into routine clinical practice remains limited [31]. This was reflected in our study, where less than one-third of patients had recorded MRD assessments, and longitudinal data were not available, potentially owing to long-term follow-up occurring outside the CAR-T-administering facility, limiting data visibility. Paired with the potential for MRD negativity to predict long-term survival, these results highlight a need for wider adoption of MRD assessment and corresponding guidelines in routine clinical practice. The range of bridging therapy regimens observed in this study reflects the highly individualized approach based on patient-level factors such as tumor burden, prior treatment exposure, and expected time from apheresis to infusion [23]. While real-world evidence evaluating bridging therapy response in this patient population is limited, the high variability in regimens observed in this study aligns with other real-world reports [32–35]. Additionally, these results generally align with those of another retrospective EMR cohort study, where 75% of patients with MM treated with CAR-T therapy in any LOT received bridging therapy [36]. The relatively higher proportion of patients observed using bridging therapy may reflect the earlier-line patient population, as well as an increased focus on the importance of bridging therapy following findings from CARTITUDE-4 and emerging real-world evidence. Talquetamab demonstrated favorable effectiveness when used as cytoreductive bridging therapy prior to cilta-cel infusion. Among evaluable patients with talquetamab as bridging therapy, ORR and MRD negativity were 100%. Given that talquetamab is indicated for patients with heavily pretreated RRMM [19, 37], and typically positioned as later-line treatment, the relatively high proportion of patients receiving it in this earlier-line setting may reflect a perceived need for highly effective disease control during the manufacturing interval [38]. Relatedly, recent updates to National Comprehensive Cancer Network (NCCN) guidelines have included talquetamab as a bridging therapy to CAR-T in RRMM [39]. This may suggest that clinicians are prioritizing deeper pre-infusion cytoreduction to optimize CAR-T outcomes even within earlier-line therapy, although these hypotheses warrant further investigation. The study findings are subject to some limitations. As with all EMR-based analyses, miscoding of data may have introduced selection or information bias. Additionally, incomplete data capture for care received outside contributing health systems may have led to misclassification and incomplete baseline data, particularly for prior treatment history, limiting our ability to assess prior treatment exposure and refractoriness (e.g., triple-class exposed/refractory and penta-refractory status). To mitigate this, unstructured physician notes were abstracted to supplement EMR data, which likely improved data completeness. Furthermore, around the time of infusion, patients tend to stay within network, ensuring a more complete capture of testing results and services received. Next, as follow-up of patients receiving cilta-cel in early-line settings remains ongoing, the ability to evaluate sustained MRD negativity was limited in the current study. This is an area for future research, where it will be important to assess longitudinal MRD outcomes among large, real-world data sources. Relatedly, the relatively short follow-up period in this study precluded assessment of long-term outcomes such as PFS and OS. The assessment of MRD was subject to potential limitations as assessments were not uniformly performed in routine practice, which may have introduced variability in measurements. Specifically, ascertainment of MRD negativity may have been nonrandom, potentially introducing selection bias and limiting the generalizability and interpretation of the observed rates. Moreover, capture of MRD negativity, including tests of deeper sensitivity (10–6), may have been limited owing to long-term follow-up received outside of specialized CAR-T-administering facilities. Nevertheless, in those with an assessment, the high MRD negativity and ORR observed may serve as promising early indicators of long-term outcomes, supporting a growing body of evidence from clinical trials. Next, safety outcomes were not within scope of the present study, but they have been evaluated in this population using the same data source in prior research [40, 41]. Additionally, some limitations in the generalizability of results may exist. First, this study required patients to have a recorded medical encounter for any reason at least 12 months prior to cilta-cel infusion, which may have excluded patients who received prior (but unobservable) MM-related care outside of the network. Second, ORR and MRD negativity were only assessed among patients with evaluable assessments. Finally, patients were identified on the basis of observed diagnosis codes and documented cilta-cel infusion, but intention-to-treat information was not available. As such, the findings should be interpreted as outcomes among infused patients and may not be generalizable to all patients referred for or intended to receive cilta-cel. Conclusions This real-world study provides important insights into the effectiveness of cilta-cel among patients with RRMM after 1–3 prior LOT in US clinical practice. The findings demonstrate high rates of response and MRD negativity shortly after infusion, highlighting rapid and effective disease control. These results are consistent across subgroups of patients receiving different bridging therapy regimens including novel treatments such as talquetamab and with findings from pivotal clinical trials. Future research with long-term follow-up and repeated MRD measurements assessed alongside clinical outcomes may provide further insights into MRD as a prognostic marker for response durability and long-term survival outcomes, helping to contextualize the potential of cilta-cel achieving a functional cure in RRMM. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (PDF 135 kb) Acknowledgments Medical Writing/Editorial Assistance Editorial assistance was provided by Lilian Diaz, MScPH, and Gordon Wong, BIE; analytical support was provided by Alvi Rahman, PhD, and Alessio Palladino, BEng, all employees of Analysis Group ULC, a consulting company that has provided paid consulting services to Johnson & Johnson. Author Contributions Sridevi Rajeeve, Saurabh P. Nagar, Sabyasachi Ghosh, Victoria Alegria, Justin Hayne, Bruno Emond, Jessica Maitland, Zaina P. Qureshi, and Larry D. Anderson Jr. have made substantial contributions to the conception or design of the study, or the acquisition, analysis, or interpretation of data, drafting the manuscript, and revising it critically for important intellectual content, and have provided final approval of this version to be published and agree to be accountable for all aspects of the work. Funding This study and the journal’s Rapid Service Fee were funded by Johnson & Johnson and Legend Biotech USA Inc. The study sponsors were involved in several aspects of the research, including the study design, interpretation of data, and editorial support. Data Availability The data that support the findings of this study are available through requests to Loopback Analytics, subject to their respective requirements for access. Restrictions apply to the availability of these data, which were used under license for this study. We thank the participants whose de-identified data contributed to the study. Declarations Conflict of Interest Sridevi Rajeeve received honoraria from Johnson & Johnson and research support from Johnson & Johnson, BMS, C4 Therapeutics, Heidelberg Pharma, and Gracell Biotechnologies; and is also part of BMS advisory board/steering committee of Gracell Biotechnologies. Saurabh P. Nagar, Sabyasachi Ghosh, Victoria Alegria, and Zaina P. Qureshi are employees and stockholders of Johnson & Johnson. Justin Hayne is an employee of Legend Biotech and owns stock/stock options in Legend Biotech. Bruno Emond and Jessica Maitland are employees of Analysis Group ULC, a consulting company that has provided paid consulting services to Johnson & Johnson. Larry D. Anderson Jr. has provided consultancy to Bristol-Myers-Squibb, Celgene, Arcellx/Kite, Karyopharm, GlaxoSmithKline, AbbVie, Johnson & Johnson, Prothena, Sanofi, Beigene, Cellectar Biosciences, and Amgen; received research funding from Bristol-Myers-Squibb, Celgene, AbbVie, and Cellectar Biosciences; received honoraria from Bristol-Myers-Squibb, Celgene, Arcellx/Kite, GlaxoSmithKline, Johnson & Johnson, Prothena, Sanofi, Pfizer, Beigene, Cellectar Biosciences, and Amgen; and participated in a Board of Directors or Advisory Committee for Celgene, Arcellx/Kite, GlaxoSmithKline, AbbVie, Karyopharm, Johnson & Johnson, Prothena, Sanofi, Pfizer, Beigene, Cellectar Biosciences, and Amgen. Ethical Approval This study was considered exempt from review by an institutional review board as it involved only the secondary use of fully de-identified data in compliance with HIPAA, specifically, 45 CFR § 164.514. Additionally, this study did not involve interaction with human subjects or access to identifiable private information. All structured and unstructured data, including physician notes, were de-identified by Loopback Analytics prior to access by the study team or third-party data abstractor, and no identifiable patient information was available to investigators at any time. Loopback Analytics’ de-identification process included removal and obfuscation of protected health information in accordance with HIPAA standards, including removal or transformation of HIPAA identifiers and replacement of direct identifiers with synthetic surrogates using a “hiding in plain sight” methodology. Accordingly, the study was considered exempt under 45 CFR § 46.104(d)(4). References Associated Data Supplementary Materials Supplementary file1 (PDF 135 kb) Data Availability Statement The data that support the findings of this study are available through requests to Loopback Analytics, subject to their respective requirements for access. Restrictions apply to the availability of these data, which were used under license for this study. We thank the participants whose de-identified data contributed to the study.